Clinical Trial Update: Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on mineralocorticoid antagonism and endothelial dysfunction in autosomal dominant polycystic kidney disease (ADPKD) with completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Snippet

Sponsor: University of Colorado, Denver | Conditions: ADPKD | Phase 3 | Status: COMPLETED | Results posted: 2019-08-20